F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comThyrocare Technologies Ltd is one of India’s leading diagnostic and preventive healthcare service providers. The company is widely known for its cost-efficient pathology services and strong pan-India network. Backed by technology-driven diagnostic testing, Thyrocare has gained significant trust among investors as a long-term player in the healthcare sector.
In this blog, we will explore Thyrocare Technologies’ share price targets from 2025 to 2030, along with its financial highlights, shareholding pattern, and future growth outlook.
| Detail | Value |
|---|---|
| Open | ₹1,266.00 |
| Previous Close | ₹1,271.70 |
| Day’s High | ₹1,306.70 |
| Day’s Low | ₹1,247.30 |
| VWAP | ₹1,278.89 |
| Market Capitalization | ₹6,811 Cr |
| Volume | 1,32,606 |
| Value (Lacs) | ₹1,704.52 |
| Beta (Volatility) | 0.32 |
| 52-Week High | ₹1,435.00 |
| 52-Week Low | ₹658.00 |
| All-Time High | ₹1,465.00 |
| All-Time Low | ₹407.15 |
| Book Value per Share | ₹92.12 |
| Face Value | ₹10 |
| Dividend Yield | 1.63% |
| 20D Avg Volume | 1,44,885 |
| 20D Avg Delivery % | 43.81% |
Founded in 1996, Thyrocare Technologies has become a trusted brand in preventive healthcare and diagnostics. The company specializes in wellness and pathology tests, with laboratories connected through a robust IT-enabled network.
Key Highlights:
Strong presence in diagnostic testing and preventive healthcare.
Technology-driven and cost-efficient diagnostic model.
Wide collection center network across India.
Consistent dividend payout, reflecting stable financials.
Lower beta (0.32), showing reduced volatility compared to broader market.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 71.06% |
| Mutual Funds | 12.66% |
| Retail & Others | 11.17% |
| Foreign Institutions | 3.23% |
| Other Domestic Institutions | 1.88% |
The high promoter holding of over 70% indicates strong confidence of the owners in the business fundamentals.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 1,350 | 1,450 |
| 2026 | 1,480 | 1,600 |
| 2027 | 1,650 | 1,800 |
| 2028 | 1,820 | 2,000 |
| 2029 | 2,050 | 2,250 |
| 2030 | 2,300 | 2,550 |
With increasing demand for preventive healthcare and diagnostic services, Thyrocare may see steady revenue growth in 2025.
Investment Advice: Consider staggered investments for long-term gains.
New diagnostic packages and expansion into Tier-2 and Tier-3 cities can boost revenue.
Investment Advice: Hold for medium to long term; good for stable portfolios.
Improved healthcare awareness and partnerships with hospitals may fuel growth.
Investment Advice: Suitable for investors seeking steady CAGR.
Expanding services in chronic disease management and digital health will support higher valuations.
Investment Advice: Strong long-term buy for defensive healthcare sector exposure.
India’s growing diagnostics market and global tie-ups could help Thyrocare gain market share.
Investment Advice: Attractive for investors looking at healthcare as a long-term wealth builder.
By 2030, Thyrocare may become a leading diagnostic player in India with high margins.
Investment Advice: Excellent stock for long-term wealth creation and dividend income.
Yes, Thyrocare Technologies Ltd is a strong healthcare stock for long-term portfolios. Its consistent financials, strong promoter confidence, and low market volatility make it a reliable option.
Leading player in diagnostics and preventive healthcare.
Stable dividend yield of 1.63%.
High promoter holding ensures stability.
Growth opportunities in wellness and chronic disease testing.
Rising competition in diagnostic space (from Dr. Lal PathLabs, Metropolis, etc.).
Price sensitivity due to affordability-driven market.
Regulatory changes in healthcare sector.
Thyrocare Technologies Ltd is a fundamentally strong company with long-term growth potential in India’s rapidly expanding healthcare industry. With its current market price around ₹1,266 and a positive growth outlook, analysts expect Thyrocare’s share price to potentially touch ₹2,550 by 2030.
For investors seeking stable returns, dividend income, and healthcare exposure, Thyrocare can be a great addition to long-term portfolios.
1. What is the next target of Thyrocare Technologies?
The next target is expected around ₹1,450 in 2025 depending on quarterly performance.
2. Is Thyrocare a good stock to buy?
Yes, it is considered a stable defensive stock in the healthcare sector with long-term potential.
3. What is Thyrocare’s 52-week high and low?
The 52-week high is ₹1,435 and the low is ₹658.
4. Does Thyrocare give dividends?
Yes, the company offers a dividend yield of around 1.63%.
5. What will be the Thyrocare share price target for 2030?
By 2030, the share price is projected between ₹2,300 – ₹2,550.
6. Is Thyrocare a high-risk stock?
No, with a beta of 0.32, Thyrocare is relatively less volatile compared to the market.
???? Disclaimer: This article is for educational purposes only. Always consult a financial advisor before making investment decisions.
Register & Login